ImmuCell Corporation (ICCC) Set to Announce Earnings on Monday
ImmuCell Corporation (NASDAQ:ICCC) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter. ImmuCell Corporation had a return on equity of 2.25% and a net margin of 4.55%. The company had revenue of $1.75 million during the quarter.
ImmuCell Corporation (NASDAQ:ICCC) opened at $8.16 on Friday. ImmuCell Corporation has a 12 month low of $4.76 and a 12 month high of $8.83. The firm has a market cap of $41.19, a PE ratio of 90.67 and a beta of 1.16. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.89 and a quick ratio of 1.28.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/12/immucell-corporation-iccc-set-to-announce-earnings-on-monday.html.
Separately, ValuEngine raised shares of ImmuCell Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 18th.
ImmuCell Corporation Company Profile
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis.
Receive News & Stock Ratings for ImmuCell Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell Corporation and related stocks with our FREE daily email newsletter.